Product Information
ARISTADA INITIO ER 675 MG/2.4 is a brand product labeled by Alkermes, Inc., priced at $1026.9112 per ML under NDC 65757050003. Its NADAC has been published 102 times since Oct 23, 2024.
FDA first approved this application on Jun 29, 2018.
Strength
675 mg/2.4mL
Manufacturer
Alkermes, Inc.NDC
65757050003
Classification
Brand
Dosage Form
INJECTION, SUSPENSION, EXTENDED RELEASE
Route
INTRAMUSCULAR
Effective Date
1/1/2026
Active Ingredients
ARIPIPRAZOLE LAUROXILApproval Type
New Drug (NDA)
FDA Application
NDA209830FDA Approved
6/29/2018
On Market Since
6/29/2018
Pharmacological Classes
Price Statistics
The NADAC for ARISTADA INITIO ER 675 MG/2.4 has been published 102 times since Oct 23, 2024, and over the history we have for it it has risen 9.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1026.9112 per ML |
|---|---|
| All-time high | $1026.9112 (Sep 30, 2026) |
| All-time low | $936.4222 (Oct 23, 2024) |
| 52-week high | $1026.9112 |
| 52-week low | $967.7065 |
| Median price | $967.7065 |
| Average price | $986.5227 |
| Largest weekly change | +6.0% (Jan 14, 2026) |
| Weeks tracked | 102 |
| Tracking since | Oct 23, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the aripiprazole lauroxil market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alkermes, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
aripiprazole lauroxil market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ARISTADA INITIO ER 675 MG/2.4?
The current National Average Drug Acquisition Cost (NADAC) for ARISTADA INITIO ER 675 MG/2.4, manufactured by Alkermes, Inc., is $1026.9112 per ML (NDC 65757050003), effective Sep 30, 2026.
How has the price of ARISTADA INITIO ER 675 MG/2.4 changed over time?
Over the history we have for it, the NADAC for ARISTADA INITIO ER 675 MG/2.4 has risen 9.7%. It has been tracked across 102 weekly CMS publications since Oct 23, 2024.
What are the highest and lowest recorded NADAC prices for ARISTADA INITIO ER 675 MG/2.4?
Since Oct 23, 2024, the NADAC for ARISTADA INITIO ER 675 MG/2.4 has ranged from a low of $936.4222 (Oct 23, 2024) to a high of $1026.9112 (Sep 30, 2026), with a median of $967.7065 per ML.
Are there cheaper alternatives to ARISTADA INITIO ER 675 MG/2.4?
No other NADAC-published product currently shares the active ingredient and strength of ARISTADA INITIO ER 675 MG/2.4 in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ARISTADA INITIO ER 675 MG/2.4?
ARISTADA INITIO ER 675 MG/2.4 (NDC 65757050003) is labeled by Alkermes, Inc., and CMS classifies it as a brand product.